2001 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Kelsen
    Kelsen
  4. Saltz
    Saltz
  5. Norton
    Norton
  6. Bajorin
    Bajorin
  7. Kemeny
    Kemeny
  8. Scher
    Scher
  9. Ilson
    Ilson
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)
  7. Gastrointestinal Oncology Service (315)
  8. Epidemiology and Biostatistics (251)
  9. Genitourinary Oncology Service (233)
  10. Biostatistics Service (223)
  1. "antineoplastic combined chemotherapy protocols"
Formats
  1. Journal Article (1861)
  2. Conference Paper (49)
  3. Review (39)
  4. Editorial (17)
  5. Research Letter (15)
  6. Miscellaneous (8)
  7. Correspondence (6)
  8. Guidelines (5)
  9. Book Section (1)
Groups
  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)

More Groups

People
  1. Nancy Kemeny (90)
  2. Robert Motzer (88)
  3. Clifford Hudis (83)
  4. David Kelsen (83)
  5. Leonard Saltz (79)
  6. Larry Norton (77)

More People

Years
  1. 2025 (46)
  2. 2024 (133)
  3. 2023 (122)
  4. 2022 (90)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (279)
  2. Cancer (171)
  3. Clinical Cancer Research (78)
  4. Seminars in Oncology (59)
  5. Gynecologic Oncology (58)
  6. New England Journal of Medicine (58)

More Publications

Publishers
  1. American Society of Clinical Oncology (294)
  2. Elsevier Inc. (276)
  3. Wiley Blackwell (212)
  4. Springer (167)
  5. Oxford University Press (113)
  6. American Association for Cancer Research (108)

More Publishers

Results (2001)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J.; Goh, J. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: A phase Ib/II study
    Journal Article

    Flowers, C. R.; Matasar, M. J.; Herrera, A. F.; Hertzberg, M.; Assouline, S.; Demeter, J.; McMillan, A.; Mehta, A.; Opat, S.; Trněný, M.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • BRAF — A tumour-agnostic drug target with lineage-specific dependencies
    Review

    Hanrahan, A. J.; Chen, Z.; Rosen, N.; Solit, D. B.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols
    Journal Article

    Valtis, Y. K.; Flamand, Y.; Shimony, S.; Place, A. E.; Silverman, L. B.; Vrooman, L. M.; Brunner, A. M.; Sallan, S. E.; Wadleigh, M.; Stone, R. M.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Journal Article

    Lee, V.; Parkinson, R.; Zahurak, M.; Cope, L.; Cercek, A.; Verheul, H.; Gootjes, E.; Lenz, H. J.; Iqbal, S.; Jones, P.; more...
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Testicular cancer in 2023: Current status and recent progress
    Review

    McHugh, D. J.; Gleeson, J. P.; Feldman, D. R.
    CA - A Cancer Journal for Clinicians (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save